Apixaban pharmacokinetic parameters
Values are the mean ± S.D., unless otherwise indicated.
| Control Group (N = 12) | NAFLD Group (N = 22) | P Value* | NAFLD-No Fibrosis Group (N = 11) | P Value* | NAFLD-Fibrosis Group (N = 11) | P Value* | |
|---|---|---|---|---|---|---|---|
| AUC0–12 (ng/ml × h) | 671 ± 174 | 545 ± 265 | 0.15 | 580 ± 228 | 0.30 | 511 ± 304 | 0.15 |
| AUC0–∞ (ng/ml × h) | 840 ± 326 | 715 ± 351 | 0.31 | 725 ± 290 | 0.38 | 705 ± 417 | 0.40 |
| Cmax (ng/ml) | 98 ± 31 | 78 ± 44 | 0.13 | 82 ± 40 | 0.33 | 74 ± 49 | 0.17 |
| Tmax (h) | 2.6 ± 1.1 | 2.7 ± 1.3 | 0.78 | 2.6 ± 1.1 | 0.96 | 2.8 ± 1.4 | 0.66 |
| t1/2 (h) | 4.5 ± 1.5 | 5.0 ± 1.2 | 0.34 | 4.5 ± 0.5 | 0.97 | 5.5 ± 1.4 | 0.12 |
| Xurine,0–12 (μg) | 611 ± 148 | 544 ± 182 | 0.26 | 527 ± 176 | 0.23 | 562 ± 194 | 0.51 |
| CLrenal (ml/min) | 16.2 ± 5.4 | 19.6 ± 9.1 | 0.25 | 17.3 ± 8.5 | 0.71 | 21.8 ± 9.4 | 0.11 |
↵* Two-tailed, t test or χ2 test with comparison with control group.